{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-063969","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.157379+00:00","generated_at":"2026-05-22T12:23:22.740830+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"OnKure Q1 net loss $15.9M, cash $96.7M; PIKture-01 trial on track for H2 2025 data","bullets":["Net loss of $15.9M ($1.19 per share) vs $9.5M in Q1 2024; R&D expense rose to $13.0M.","Cash and cash equivalents of $96.7M expected to fund operations into Q4 2026.","PIKture-01 Part A monotherapy enrollment closed; mature data expected H2 2025.","Part B fulvestrant combo dose escalation nearing completion; initial data in H2 2025.","Pan-mutant PI3Kα development candidate to be announced in Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-063969","json":"https://secwatch.observer/filing/0000950170-25-063969.json","markdown":"https://secwatch.observer/filing/0000950170-25-063969.md","text":"https://secwatch.observer/filing/0000950170-25-063969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000095017025063969/0000950170-25-063969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000095017025063969/okur-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T12:23:22.740830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}